Amy Miller
Family · Walker, LANPI 1851900385
Payments from drug & device makers
Across 205 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$473
- AbbVie$308
- Merck$302
- Takeda Pharmaceuticals U.S.A., Inc.$294
- Collegium Pharmaceutical, Inc.$264
- Bayer$241
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $473 |
| AbbVie | 25 | $308 |
| Merck | 17 | $302 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $294 |
| Collegium Pharmaceutical, Inc. | 13 | $264 |
| Bayer | 12 | $241 |
| Boehringer Ingelheim | 13 | $234 |
| Saluda Medical Americas, Inc. | 5 | $171 |
| Johnson & Johnson | 11 | $161 |
| Boston Scientific | 2 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| Novo Nordisk | 7 | $118 |
| GSK | 7 | $117 |
| Averitas Pharma Inc. | 4 | $99 |
| Corium, LLC | 4 | $64 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Adlon Therapeutics L.p. | 3 | $52 |
| Medtronic | 1 | $50 |
| Merz North America, Inc. | 1 | $43 |
| Lundbeck LLC | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Dynavax Technologies Corporation | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 2 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $24 |
| Bioventus LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
| Novartis | 1 | $18 |
| Neos Therapeutics, LP | 1 | $18 |
| Pfizer | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$102
How this compares
$3,763 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $44,939 |
| MounjaroTirzepatide | 26 | $30,661 |
| JardianceEmpagliflozin | 13 | $15,473 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $12,532 |
| XareltoRivaroxaban | 14 | $7,411 |
| Atorvastatin Calcium | 96 | $885 |
| Omeprazole | 50 | $679 |
| Gabapentin | 49 | $522 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $512 |
| Trazodone Hcl | 40 | $479 |
| Buspirone Hcl | 16 | $417 |
| Metoprolol Succinate | 25 | $393 |
| Pravastatin Sodium | 32 | $380 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $374 |
| Losartan Potassium | 37 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $118 | $44,93935 claims |
| Lilly USA, LLCMounjaro | $473 | $30,66126 claims |
| Boehringer IngelheimJardiance | $234 | $15,47313 claims |
| Johnson & JohnsonXarelto | $161 | $7,41114 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $29435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Walker
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.